In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PharmaNetics Inc.

Latest From PharmaNetics Inc.

The New Diagnostics Companies

A small number of start-ups are developing novel specilalty-focused diagnostics that capture drug-like revenues and margins without taking drug-like development and regulatory risks. Questions about the business model abound, since most companies need multiple tests to reach profitability and a changing regulatory climate may force these companies to seek FDA approval for their tests, dramatically increasing development risk and cost.

BioPharmaceutical Medical Device

The Challenge of Making Money from Biomarkers

VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business model

BioPharmaceutical Medical Device

The Outlook for Pharmacogenomics Testing in Primary Care

The FDA sees pharmacogenomics as a key tool for optimizing both the development and clinical utility of drugs. But most of the visible examples to date of pharmacogenomics have been in specialty areas like oncology and virology. The Vioxx situation raises an inevitable question as Pharma looks to improve R&D efficiency and clinical utility. What is the role of pharmacogenomics in assessing the safety and efficacy of primary care drugs?

Medical Device Platform Technologies

Marketers' Views of Changing Cardiology Practice Patterns

The history of the IIb/IIIa inhibitor Integrilin touches on many of the challenges of cardiology marketing, including how to move a member of a new class of drugs into a complex, rapidly evolving treatment pattern. Having established Integrilin as the most-used drug in its class, its marketer must now deal with the impact on IIb/IIIa use of Angiomax, a potential replacement for heparin. Imagine the scene five years from now: A combination of Angiomax and low-molecular-weight heparin has replaced unfractionated heparin, and the addition of statins and possibly vascular protectants has turned the current triple therapy regimens of anti-coagulants, anti-thrombins, and anti-platelet drugs into a quartet. Physicians attending scientific meetings may well still be puzzling over the proper role of IIb/IIIa inhibitors, and asking themselves the extent to which long-term results from trials initiated early in the 21st century have meaning.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring